Navigation Links
Reportlinker Adds IP Overview - "Monoclonal Antibodies against digestive system cancers" Patent Landscape 2010

NEW YORK, Sept. 21 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

IP Overview – "Monoclonal Antibodies against digestive system cancers" Patent Landscape 2010–-"Monoclonal-Antibodies-against-digestive-system-cancers"-Patent-Landscape-2010.html

In order to fight digestive system cancers, monoclonal antibody-based therapies have recently reinforced the range of already marketed treatments (mostly constituted of small molecules) and are generating important revenues. Four antibodies have already been approved but new ones are still needed. Many players are therefore trying to position themselves on this sector. This has resulted in an active patent policy that has nevertheless reached a plateau since 2005.

The present report analyses the patent environment and highlights the various monoclonal antibodies that have been developed to diagnose and treat oesophageal, gastric, bile duct, gastro-intestinal, colorectal, hepatic, pancreatic and anal cancers. The major trend is the development of human immunoconjugates against colorectal cancers by targeting growth factor receptors. Although this sector is surrounded by Roche and its subsidiaries, other players, and especially big pharma and biotech companies, continue to develop antibodies targeting new antigens and/or having new properties.

In this competitive sector driven by an important market and where 3000 patent families have been filed, this study « IP Overview – Monoclonal antibodies against digestive system cancers» provides you with a comprehensive panorama of the intellectual property landscape and helps you:

- Position your company's R&D and IP Portfolio

- Identify key inventors and key players involved in the development of new monoclonal antibodies

- Understand the collaboration networks and their dynamics

- Discover new trends and emerging topics

Please note that a three months access to the full patent database is also included

Table of contents Brief outline of the technologyGeneralitiesBrief outline of the market - 2009

Patent query

Brief outline of the pipeline - 2010

Evolution of patent filings (1988-2008)

Evolution of the number of applicants

Industrial & institutional filings over time

Map of extensions

Map and evolution of priority filings

Evolution and location of patent filingsMain applicants on the entire period (1988-2008)

Part of the portfolio hold by the first 10 applicants

Breakdown of filings of the main industrial/institutional applicants over time

Main applicants in the last 4 years (2005-2008)

Main co-filings between applicants

Analysis of patent applicantsAnalysis of inventors

List of the main inventors

Main research teams

Emerging inventors

Topics of patent filingsBreakdown of the portfolio (for each breakdown is presented the evolution of filings

and the positioning of institutional applicants, industrial applicants and inventors)

1/Type of monoclonal antibodies

2/Targets of monoclonal antibodies

2.1/Growth factor receptors

2.2/Molecules involved in cell adhesion

2.3/Other targets

3/Type of digestive system cancers targeted by mAbs

Focus on ROCHEOrganization chart

Distribution and evolution of patent filings by subsidiaries

Filing policy

Topics of patent applications


Citation & Extension AnalysisList of the most cited patents and patent applications

Positioning of patent applications portfolio via citation analysis

Most extended patents

Coverage rate classification

ConclusionAppendicesmAbs clinical trials by company


To order this report:Biological Therapy Industry: IP Overview – "Monoclonal Antibodies against digestive system cancers" Patent Landscape 2010

Biological Therapy Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:  Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
2. Reportlinker Adds Prosthetic Heart Valves - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
3. Reportlinker Adds U.S. Market for Cardiac Rhythm Management, Electrophysiology and Ablation Devices 2010
4. Reportlinker Adds Canadian Dental Market Overview & Dentist Survey 2010 (Implants, Prosthetics, Imaging & CAD/CAM)
5. Reportlinker Adds ENT Devices Market Outlook in Argentina to 2016 - Hearing Aid Devices and Implants and Diagnostic Devices
6. Reportlinker Adds Healthcare IT Market Outlook in China to 2016 - Hospital Information Systems and Medical Imaging Information Systems
7. Reportlinker Adds Interventional Cardiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
8. Reportlinker Adds Clinical Trial Patient Recruitment: Accelerate Enrollment, Increase Retention and Reduce Costs
9. Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
10. Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
11. Reportlinker Adds Cardiovascular Surgery Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
Post Your Comments:
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from reveals that behind the ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
Breaking Medicine News(10 mins):